Key Points
- CFO Jerome Wong sold 11,288 shares on Nov. 10 at an average price of $4.80 for proceeds of about $54,182, cutting his stake by 30.27% to 26,009 shares (worth ≈ $124,843).
- Ekso shares traded around $5.14 (50‑day avg $4.80, 200‑day avg $16.80) with a market cap of ~$13.5M; the company reported Q EPS of ($0.54) that beat estimates and revenue of $4.23M, but still shows a negative net margin (~70.7%) and negative ROE (~90.7%).
- Institutional and analyst activity is mixed: Consolidated Portfolio Review Corp acquired 64,883 shares (~2.47% of the company) while analysts range from Buy to Sell, with Weiss Ratings reaffirming a "sell (e+)" and MarketBeat showing a consensus "Hold."
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO - Get Free Report) CFO Jerome Wong sold 11,288 shares of the company's stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $54,182.40. Following the completion of the sale, the chief financial officer directly owned 26,009 shares in the company, valued at approximately $124,843.20. The trade was a 30.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.
Ekso Bionics Stock Performance
Shares of NASDAQ EKSO traded down $0.31 during midday trading on Thursday, hitting $5.14. 29,091 shares of the company's stock were exchanged, compared to its average volume of 116,847. Ekso Bionics Holdings, Inc. has a 12 month low of $2.73 and a 12 month high of $14.97. The company's 50 day moving average price is $4.80 and its 200 day moving average price is $16.80. The company has a quick ratio of 1.57, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $13.48 million, a PE ratio of -0.90 and a beta of 1.08.
Ekso Bionics (NASDAQ:EKSO - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.45. The company had revenue of $4.23 million for the quarter, compared to analyst estimates of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. As a group, analysts predict that Ekso Bionics Holdings, Inc. will post -0.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ekso Bionics
A hedge fund recently bought a new stake in Ekso Bionics stock. Consolidated Portfolio Review Corp bought a new position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 64,883 shares of the company's stock, valued at approximately $333,000. Consolidated Portfolio Review Corp owned approximately 2.47% of Ekso Bionics as of its most recent filing with the SEC. 6.42% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ekso Bionics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $562.50.
View Our Latest Analysis on Ekso Bionics
About Ekso Bionics
(
Get Free Report)
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
